Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis

Osteoarthritis Cartilage. 2011 Jul;19(7):874-85. doi: 10.1016/j.joca.2011.04.014. Epub 2011 May 12.

Abstract

Objectives: To investigate the regulation of sclerostin (SOST) in osteoarthritis (OA) and its potential effects on articular cartilage degradation.

Methods: SOST and other Wnt-β-catenin components were immuno-localised in osteochondral sections of surgically-induced OA in knees of sheep and mice, and human OA samples obtained at arthroplasty. Regulation of SOST mRNA and protein expression by ovine chondrocytes in response to interleukin-1α (IL-1α) or tumour necrosis factor-α (TNFα) was examined in explant cultures. The effect of 25 or 250 ng/ml recombinant SOST alone or in combination with IL-1α, on ovine articular cartilage explant aggrecan degradation, and chondrocyte gene expression of Wnt-β-catenin pathway proteins, metalloproteinases and their inhibitors, and cartilage matrix proteins was quantified.

Results: Contrary to being an osteocyte-specific protein, SOST was expressed by articular chondrocytes, and mRNA levels were upregulated in vitro by IL-1α but not TNFα. Chondrocyte SOST staining was significantly increased only in the focal area of cartilage damage in surgically-induced OA in sheep and mice, as well as end-stage human OA. In contrast, osteocyte SOST was focally decreased in the subchondral bone in sheep OA in association with bone sclerosis. SOST was biologically active in chondrocytes, inhibiting Wnt-β-catenin signalling and catabolic metalloproteinase [matrix metalloproteinases (MMP) and distintegrin and metalloproteinase with thrombospndin repeats (ADAMTS)] expression, but also decreasing mRNA levels of aggrecan, collagen II and tissue inhibitors of metalloproteinaes (TIMPs). Despite this mixed effect, SOST dose-dependently inhibited IL-1α-stimulated cartilage aggrecanolysis in vitro.

Conclusions: These results implicate SOST in regulating the OA disease processes, but suggest opposing effects by promoting disease-associated subchondral bone sclerosis while inhibiting degradation of cartilage.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Morphogenetic Proteins / metabolism*
  • Cartilage, Articular / drug effects
  • Cartilage, Articular / metabolism*
  • Cartilage, Articular / pathology
  • Chondrocytes / drug effects
  • Chondrocytes / metabolism*
  • Humans
  • Interleukin-1alpha / pharmacology
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Mice
  • Osteoarthritis, Knee / metabolism*
  • Osteoarthritis, Knee / pathology
  • RNA, Messenger / metabolism
  • Sheep
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Bone Morphogenetic Proteins
  • Interleukin-1alpha
  • Intracellular Signaling Peptides and Proteins
  • RNA, Messenger
  • Tumor Necrosis Factor-alpha